Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. It operates through the following segments: Radiation Therapy, Isotope Products, and Radiopharma. The Radiation Therapy segment includes the production and distribution of medical products for the treatment of cancer using brachytherapy. The Isotope Products segment manufactures and distributes sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration, and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic, and industrial product manufacturers. The Radiopharma segment specializes in the field of molecular imaging and nuclear medicine; and supplies different radiopharmaceuticals, radiochemicals, and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. The company was founded by Andreas Eckert in 1997 and is headquartered in Berlin, Germany.
Personnel at the end of the year
Staff turnover in EUR
The share: stated in EUR
Shares outstanding (in mn.)
Dividend per share
Basic earnings per share
P/L in EUR million under IAS/IFRS
Operating income (EBIT)
Earnings before taxes
Annual net profit/ loss
Balance sheet in EUR million under IAS/IFRS
Total current assets
Total fixed assets
Total short-term liabilities
Total long-term liabilities
Shareholding in %:
Columbia Wanger Asset Management LLC
Dimensional Fund Advisors LP
Eckert & Ziegler Strahlen- und Medizintechnik AG
Invesco Canada Ltd.
JPMorgan Asset Management (UK) Ltd.
Joh. Berenberg, Gossler & Co. KG (Investment Management)
KBC Asset Management NV
Lupus alpha Asset Management AG
The Vanguard Group, Inc.
Robert-Roessle-Strasse 10, 13125 Berlin
No 1 issuer of certificates
For the fifteenth time in a row, Raiffeisen Centrobank was named Austria's best certificate issuer.
Content made available on this website and on its sub-sites (jointly, the “Site”) is provided for information purposes only (“Information”) and must not be considered as financial analysis or any other form of recommendation. The Information is not intended to be used as a substitute for investment advice. There is no obligation of Raiffeisen Centrobank AG (“RCB”) to keep the Information up-to-date.
Nothing contained herein should be considered as an offer or a solicitation of an offer to sell or to purchase any Securities issued by RCB (the “Securities”). The sole legal basis for any Securities issued by RCB is the respective published prospectus of the Structured Notes Programme of RCB which has been duly approved by the Austrian Financial Market Authority jointly with the applicable final terms, all of which are available for download on this website.
Public offers of securities which are based on a prospectus published on the following website are made by RCB exclusively to persons residing in one of the following member states: Republic of Austria, Republic of Croatia, Czech Republic, Federal Republic of Germany, Hungary, Italian Republic, Republic of Poland, Romania, Slovak Republic, and Republic of Slovenia (the “Offer Member States”). The respective product information for each of the Securities specifies in which of the Offer Member States the relevant issue of the Securities is publicly offered in accordance with the applicable rules at a given time; said data is available for download under the category “Public offer in” which can be accessed via www.rcb.at/en/investment-products/investment-products/overview/ or www.rcb.at/en/leverage-products/leverage-products/overview/. Persons who are not resident in such Offer Member State(s) are excluded from public offers of the Securities and are not targeted.
The Information is not addressed to persons residing in countries where distributing the Information would be illegal. Information, in whole or part, must not be retransmitted or distributed to persons from countries where such retransmission or distribution would be illegal, in particular to US nationals or to U.S. Persons (“U.S. Persons” within the meaning of Regulation S of the U.S. Securities Act of 1933, as amended, the “U.S. Securities Act”), as well as to Australian, Canadian, British or Japanese nationals or residents. Persons residing in these countries are not allowed to access this Site.
In particular, the Information provided on this Site is not assigned for persons residing in the USA and/or U.S. Persons. U.S. Persons and other U.S. residents are not allowed to access this Site. The Information provided on this Site may neither be distributed nor published in the USA, nor may any Securities, subject to certain exceptions, be sold or offered in the USA, to U.S. persons and/or to other U.S. residents. The Securities neither have been nor will be registered under the U.S. Securities Act, nor with any securities regulatory authority of any state or other jurisdiction of the USA, and are subject to U.S. tax law requirements. Trading in the Securities has not been approved for purposes of the U.S. Commodities Exchange Act of 1936. For this reason, the Securities may, inter alia, not be offered, sold or delivered within the United States or for the account and benefit of a U.S. person.
In spite of all due care given, RCB assumes no warranty nor does RCB make or give any representation as to the Information being reliable, accurate, complete, up to date, adequate or suitable for a specific purpose, nor that the access to the Site will be uninterrupted or error free. Past performance is not indicative of future results whatsoever. Trading with Securities involves financial risks and may even result in the partial or complete loss (total loss) of the invested capital.
The content on this Site is protected by trade mark, copyright and other intellectual property laws and is duly owned or used by RCB. Any reproduction or distribution of the Information in part or in whole is prohibited without RCB’s prior permission. RCB reserves the right to amend the terms set forth herein at any time. Amendments will be published on the Site. Users will be deemed to have accepted these amendments when continuing to use the Site.
CONFIRM: The user hereby explicitly confirms to consent to the terms set forth herein and of having been informed of all restrictions applicable to him/her. The user warrants that his/her access to this Site is neither restricted nor prohibited in accordance with the rules and laws applicable to him/her. The user further undertakes that he/she will not transmit or otherwise make available any Information contained in this Site to any person not being entitled to access this Site according to the applicable law.
CANCEL: The user hereby explicitly refuses to consent to the terms set forth herein.